Effective Arrestin–Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis

Abstract

Successful therapies for autoimmune uveitis must specifically inhibit pathogenic inflammation without inducing generalized immunosuppression. RTLs can offer such an option. The single retina-specific RTLs may have a value as potential immunotherapeutic drug for human autoimmune uveitis because they effectively prevent disease induced by multiple T cell specificities.

Blood-retina barrier dysfunction in experimental autoimmune uveitis: the pathogenesis and therapeutic targets

“…EAU-induced rats are showed the monophasic and spontaneous pan-uveitis [ 8 ]. Furthermore, HLA transgenic mice indicate the pan-uveitis, vasculitis, granuloma formation, photoreceptor damage, and retinal folding and/or detachment [ 4 , 9 ]. The neuropathogenesis of EAU is complex and involves multiple factors, including proliferation of autoimmune T cells, activation of antigen-presenting cells, homing of autoimmune T cells to the eyes with concurrent activation of adhesion molecules, inflammation in the uvea and retina with glial activation, and finally disruption of visual function and occasionally blindness [ 5 - 7 ].…”